Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Allan Steven Jacobson net worth and biography

Allan Jacobson Biography and Net Worth

Director of PTC Therapeutics

Allan Jacobson, Ph.D. is a co-founder of PTC and is the Gerald L. and Zelda S. Haidak Distinguished Professor of Cell Biology at the University of Massachusetts Chan Medical School. He has served as a member of the PTC board of directors since the company’s inception in 1998, previously served as Chairman of the board of directors from 1998 to 2004, and, since 2000, has served as Chairman of the scientific advisory board. In 1982, Dr. Jacobson co-founded Applied bioTechnology, Inc., a biotechnology company, and served as its chairman until its sale in 1991. From 1987 to 1990, Dr. Jacobson served as special limited partner at Euclid Partners, a venture capital firm. Dr. Jacobson has been the Chairman of the Department of Microbiology and Physiological Systems at the UMass Chan Medical School since 1994, and in 2014, was awarded the Medical School’s Chancellor’s Medal for Distinguished Scholarship. Dr. Jacobson received a Ph.D. from Brandeis University in 1971, has authored over 100 publications in the field of post-transcriptional control processes, and is an elected member of the American Academy of Microbiology and the American Academy of Arts and Sciences.

What is Allan Steven Jacobson's net worth?: The estimated net worth of Allan Steven Jacobson is at least $518,122.08 as of January 22nd, 2024. Dr. Jacobson owns 12,348 shares of PTC Therapeutics stock worth more than $518,122 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Jacobson may own. Additionally, Dr. Jacobson receives an annual salary of $145,000.00 as Director at PTC Therapeutics. Learn More about Allan Steven Jacobson's net worth.
How old is Allan Steven Jacobson?: Dr. Jacobson is currently 78 years old. There are 7 older executives and no younger executives at PTC Therapeutics. Learn More on Allan Steven Jacobson's age.
What is Allan Steven Jacobson's salary?: As the Director of PTC Therapeutics, Inc., Dr. Jacobson earns $145,000.00 per year. There are 6 executives that earn more than Dr. Jacobson. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Allan Steven Jacobson's salary.
How do I contact Allan Steven Jacobson?: The corporate mailing address for Dr. Jacobson and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Allan Steven Jacobson's contact information.
Has Allan Steven Jacobson been buying or selling shares of PTC Therapeutics?: Allan Steven Jacobson has not been actively trading shares of PTC Therapeutics during the last ninety days. Most recently, Allan Steven Jacobson sold 10,000 shares of the business's stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $27.38, for a transaction totalling $273,800.00. Following the completion of the sale, the director now directly owns 12,348 shares of the company's stock, valued at $338,088.24. Learn More on Allan Steven Jacobson's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 7/16/2024.

Allan Steven Jacobson Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2024	Sell	10,000	$27.38	$273,800.00	12,348
5/11/2023	Sell	23,000	$55.08	$1,266,840.00	12,348
10/16/2020	Sell	5,000	$51.29	$256,450.00	3,498
4/20/2020	Sell	17,900	$51.04	$913,616.00	10,598
4/17/2020	Sell	2,100	$50.16	$105,336.00	10,598
6/18/2015	Sell	5,000	$50.13	$250,650.00
3/18/2015	Sell	16,616	$76.00	$1,262,816.00
9/18/2014	Sell	2,000	$40.16	$80,320.00
3/18/2014	Sell	7,616	$31.18	$237,466.88	30,464

Allan Steven Jacobson Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $41.96

$38.26

$42.79

50 Day Range

MA: $38.72

$32.27

$44.87

2 Week Range

Now: $41.96

$20.75

$46.98

Volume

722,545 shs

Average Volume

766,640 shs

Market Capitalization

$3.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Allan Jacobson Biography and Net Worth

What is Allan Steven Jacobson's net worth?

How old is Allan Steven Jacobson?

What is Allan Steven Jacobson's salary?

How do I contact Allan Steven Jacobson?

Has Allan Steven Jacobson been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?